The acquisition expands Prometheus Group’s intelligent operations platform.
Merck’s MRK $10.8 billion acquisition of Prometheus Biosciences adds the well-positioned late-stage immunology drug PRA023 at largely a fair price, in our view. We don’t expect any major changes to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback